A mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential and its sorting method and application
Through single-cell sequencing and flow cell sorting technology, MSC subpopulations with high osteogenic cartilage potential were identified and isolated, which solved the problem of different treatment effects caused by mesenchymal stem cell heterogeneity, and achieved standardization of MSC population and The stronger osteogenic cartilage differentiation function significantly improves the treatment effect of knee osteoarthritis.
Patent Information
- Application Number
- CN202410958820.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-07-17
AI Technical Summary
The heterogeneity of mesenchymal stem cells, the number of injections, allogeneic or autologous sources lead to differences in the treatment effect of knee osteoarthritis. Traditional studies mostly target the entire cell population, which masks the differences in the functions and genome expression of different cell subpopulations, and hinders the Research on biological characteristics and clinical applications.
Subpopulations of clinical treatment-level MSCs were subpopulated by single-cell sequencing, and subpopulation of cells with high osteogenic cartilage potential were identified and isolated. Flow cell sorting was used using PDGFRA, IL1R1 and IL18R1 as markers to obtain high yield MSC subpopulation of osteocartilage potential (CHON-MSC).
The standardization of the MSC population has been achieved, the osteogenic cartilage differentiation function has been enhanced, the polarization of M1 type macrophages has been inhibited, the polarization of M2 type macrophages has been promoted, the apoptosis of chondrocytes has been inhibited, and the cartilage differentiation ability has been significantly improved, and the The therapeutic efficacy of knee osteoarthritis and provides more efficient MSC products.
Smart Images

Figure CN118497121B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of cell separation and purification, and specifically relates to a mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential, and a sorting method and application thereof. Background Art
[0002] Mesenchymal stem cells (MSC), also known as multipotent mesenchymal stromal cells, are a multilineage progenitor cell population with a fibroblast-like morphology that was first observed in the bone marrow. They can differentiate into osteoblasts, chondrocytes, and adipocytes under specific conditions in vitro. In knee osteoarthritis (OA), mesenchymal stem cells can treat knee OA through immunomodulatory effects and tissue repair functions. Compared with existing drug treatments and surgical treatments, mesenchymal stem cells do not have common side effects such as bone marrow suppression, liver damage, and increased risk of postoperative infection. Therefore, they have broad prospects for clinical application. Mesenchymal stem cell transplantation may become a widely used immune cell therapy for the treatment of knee OA.
[0003] Although intra-articular injection of mesenchymal stem cells can effectively relieve pain in patients with knee osteoarthritis and has a positive effect on tissue regeneration, there are still major differences. The reasons for this are that the heterogeneity of mesenchymal stem cells, the number of injections, and the source of allogeneic or autologous cells are all reasons for the differences in treatment effects. Among them, as a group of mixed cell populations, the influence of the heterogeneity of mesenchymal stem cells on biological characteristics has attracted more and more attention and is considered to be the main factor leading to different clinical effects. The relatively low proportion of effective cells in the heterogeneous population limits its further application in clinical practice. Mesenchymal stem cells from different individuals, different tissue types, different clonal subpopulations, and different isolation and amplification technologies have different phenotypes and properties. Therefore, the mesenchymal stem cells traditionally used for clinical treatment have subpopulations with different gene expression profiles and different phenotypes, and they exist in different proportions, and the growth rate, function, and differentiation direction of each subpopulation are not the same. Previous studies have mostly focused on the entire mesenchymal stem cell population, and the results obtained are likely to mask the differences in function and genomic expression between different cell subpopulations. These reasons have greatly hindered the relevant research and application between MSC subpopulations and their specific biological characteristics, and are not conducive to improving the clinical efficacy of mesenchymal stem cells in the treatment of knee osteoarthritis.
[0004] Therefore, in-depth and systematic exploration of the composition of each subpopulation and finding the optimal type of mesenchymal stem cells required for the treatment of knee osteoarthritis are key issues in solving its clinical application. Summary of the invention
[0005] Technical problems to be solved: In response to the above technical problems, the present invention provides a mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential and a sorting method and application thereof, which can effectively solve the shortcomings of the above-mentioned mesenchymal stem cells, such as heterogeneity, injection quantity, allogeneic or autologous source, which cause differences in therapeutic effects; and identify and separate cell subpopulations of MSC in each culture system and clarify their functions, thereby achieving standardization of MSC populations, which is of great significance for promoting their effective transformation into clinical applications.
[0006] Technical solution: In the first aspect, the present invention provides a mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential, and uses single-cell sequencing to subdivide clinical treatment-level MSCs. The cell subpopulation with the most concentrated distribution of osteogenic and chondrogenic differentiation regulatory genes in each subpopulation is the MSC subpopulation with high osteogenic and chondrogenic potential.
[0007] Preferably, the MSC subpopulation with high osteogenic and chondrogenic potential simultaneously highly expresses PDGFRA, IL1R1 and IL18R1 on the cell surface.
[0008] In a second aspect, the present invention provides a method for sorting a subpopulation of mesenchymal stem cells with high osteogenic and chondrogenic potential as described in the first aspect, comprising the following steps: surface staining clinical treatment-grade MSCs with a combination of flow cytometry antibodies labeled with different fluorescent markers, resuspending the stained cells in PBS and then sorting them using a flow cytometer; the antibody combination includes antibodies that recognize antigens PDGFRA, IL1R1 and IL18R1.
[0009] In a third aspect, the present invention provides use of the mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential described in the first aspect in the preparation of a drug for treating bone and joint diseases.
[0010] Preferably, the osteoarthritis includes knee osteoarthritis.
[0011] In a fourth aspect, the present invention provides use of the mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential described in the first aspect in the preparation of a drug for treating osteoporosis.
[0012] Beneficial effects: The present invention utilizes single-cell sequencing technology to perform subgroup segmentation on MSC cells at the traditional clinical treatment level, and sorts out MSC subgroups (CHON-MSC) with stronger osteogenic and chondrogenic differentiation functions. Compared with traditional MSC, CHON-MSC has a stronger ability to inhibit M1 macrophage polarization and promote M2 macrophage polarization, a stronger ability to inhibit chondrocyte apoptosis, and a stronger ability to differentiate into chondrocytes. CHON-MSC has a better therapeutic effect in the in vitro treatment of osteoarthritis, especially the treatment of OA. The present invention also realizes the sorting preparation of CHON-MSC, which can be stably expressed in vitro after sorting, providing a more efficient MSC product for MSC treatment of autoimmune diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 This is a schematic diagram of the positive identification results of three surface markers of MSCs at the traditional clinical treatment level;
[0014] Figure 2 This is a schematic diagram of the negative identification results of five surface markers of MSCs at the traditional clinical treatment level;
[0015] Figure 3 This is a schematic diagram of the staining results of MSC tri-lineage differentiation at the traditional clinical treatment level;
[0016] Figure 4 This is a schematic diagram of the results of single-cell analysis of different MSC cell subsets;
[0017] Figure 5 This is a diagram showing the results of flow sorting and amplification of CHON-MSCs of the present invention;
[0018] Figure 6 This is a comparison diagram of the effects of CHON-MSC of the present invention and traditional MSC on polarization of M0 macrophages;
[0019] Figure 7 This is a comparison diagram of the effects of CHON-MSC of the present invention and traditional MSC on chondrocyte apoptosis;
[0020] Figure 8 This is a comparison chart of the chondrogenic differentiation ability of CHON-MSC of the present invention and traditional MSC;
[0021] Fig. 9 This is an X-ray image of the osteoarthritis animal model experiment in Example 5. DETAILED DESCRIPTION
[0022] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments:
[0023] Example 1: Isolation of CHON-MSCs
[0024] 1. Identification of MSCs at the traditional clinical treatment level
[0025] The identification results are as follows Figure 1-Figure 3 As shown, among which, Figure 1 As shown: The cells at passage 4 were positive for CD73, CD90 and CD105 as identified by flow cytometry; Figure 2 As shown: The cells at passage 4 were negative for CD45, CD34, CD11b, CD19 and HLA-DR as determined by flow cytometry; Figure 3The results of osteogenic differentiation-Alizarin red staining, chondrogenic differentiation-Alcian blue staining and adipogenic differentiation-Oil Red O staining of traditional MSCs indicate that the quality of MSC products is good, there is no contamination of other cell types, and that they have tri-lineage differentiation function;
[0026] 2. MSC single-cell transcriptome sequencing
[0027] We commissioned New Gene (Nanjing) Biotechnology Co., Ltd. to perform hUC-MSC single-cell sequencing and perform UMAP analysis on the sequencing data, further dividing MSC cells into 8 subgroups (Clusters): Compared with other subgroups, osteogenic and chondrogenic differentiation regulatory genes (COL11A1, COL1A1, COL1A2, COL3A1, EFEMP1, HAND2, HOXA11, TNFAIP6, SNAI2, IGFBP3, SULF2, TGFBI, TWSG1, KLF10, MMP2, ZBTB16, ATF4, TMEM119, CDH11, CEBPB and CEBPD) were most concentrated in Cluster 2. The results are as follows: Figure 4 As shown: Among them, Figure 4 a in the figure is UMAP clustering. Figure 4 Middle b is a heat map of osteochondrogenic differentiation regulatory genes in different subgroups of MSC. It can be seen that Cluster 2 expresses the most osteochondrogenic differentiation regulatory genes, so this group of cells with the strongest osteochondrogenic differentiation potential is defined as a mesenchymal stem cell subgroup with high osteochondrogenic potential (abbreviated as CHON-MSC);
[0028] Compared with traditional MSCs, CHON-MSCs expressed significantly higher levels of osteogenic and chondrogenic differentiation regulatory genes. GO enrichment analysis was used to analyze the biological functions of the 8 cluster differentially enriched genes. The results are shown in Table 1 below:
[0029] Table 1 Significant signaling pathways involved in each MSC cell subset
[0030] ,
[0031] As shown in Table 1, Cluster 2 (CHON-MSC) has similar biological functions, mainly regulating chondrogenic differentiation and osteogenic differentiation, indicating that its strong osteogenic and chondrogenic abilities can treat diseases caused by bone or cartilage damage, and provide a new strategy for the clinical application of hUC-MSC (umbilical cord mesenchymal stem cells). By querying some genes with the highest gene expression levels in CHON-MSC compared to traditional MSC, PDGFRA, IL1R1 and IL18R1 were selected as surface genes that can be used to flow-sort CHON-MSC; and after CHON-MSC is sorted, CHON-MSC can be stably expanded in vitro;
[0032] 3. Isolation and expansion of CHON-MSCs
[0033] Staining system: 1×10 6 5 μL APC fluorescently labeled IL1R1 flow cytometry antibody, 5 μL FITC fluorescently labeled IL18R1 flow cytometry antibody, 5 μL PE fluorescently labeled PDGFRA flow cytometry antibody and 90 μL PBS were added to each MSC for staining;
[0034] After the system was prepared, the cells were stained at 4 °C in the dark for 30 min, washed once with 1 mL PBS (4 °C, 500 × g, centrifuged for 5 min), resuspended in 1 mL PBS, and sorted by flow cytometry for the above fluorescence-positive MSC subpopulations. The sorted cells were the CHON-MSCs. Figure 5 Shown: CHON-MSCs were successfully isolated and could be stably expanded in vitro.
[0035] Example 2: In vitro verification that CHON-MSCs have a stronger ability to inhibit M1 macrophage polarization
[0036] (A) THP-1 cells were obtained from the Cell Bank of the Chinese Academy of Sciences;
[0037] (II) Main reagents: DMEM / F12 culture medium, Corning, USA; Phorbol myristate (PMA), Merck, Germany; Lipopolysaccharide (LPS), MCE, USA; IFN-γ (interferon-γ), Proteintech, USA; 0.25% trypsin-0.02% EDTA, Gibco, USA; Flow cytometry antibodies: APC CD163, FITC HLA-DR, PerCP-Cy5.5 CD206 and PECD86, purchased from BD, USA; Cell culture equipment: 100 mm diameter cell culture dishes and cell culture plates; For those whose specific techniques or conditions are not specified in the examples, the techniques or conditions described in the literature in this field or the product instructions shall be followed; for those whose manufacturers are not specified in the reagents or instruments used, they can be purchased through regular channels;
[0038] (III) Solution preparation:
[0039] DMEM / F-12 complete medium: add 450 mL of DMEM / F12 medium to 50 mL of FBS (fetal bovine serum), then add penicillin 100 IU / mL (final concentration) and streptomycin 100 μg / mL (final concentration);
[0040] (IV) Staining protocol for M1 and M2 macrophages: Macrophages were resuspended in 100 μL PBS and transferred to flow cytometry tubes. 1×10 6 5 μL APC anti-human-CD163 antibody, 20 μL FITC anti-human-HLA-DR antibody, 5 μL PerCP-Cy5.5 anti-human-CD206 antibody and 5 μL PE anti-human-CD86 antibody were added to each cell and incubated at room temperature in the dark for 30 min. After adding 1 mL PBS, centrifuge at 500 g / min for 5 min, repeat twice, and resuspend in 100 μL PBS for loading;
[0041] 5. Flow cytometry staining results Figure 6 As shown: Compared with traditional MSCs, CHON-MSCs down-regulate M1 macrophages (such as Figure 6 As shown in a), upregulation of M2 macrophages (as shown in Figure 6 The expression of CHON-MSCs was higher than that of traditional MSCs, indicating that CHON-MSCs can better inhibit the polarization of M1 macrophages and promote the polarization of M2 macrophages than traditional MSCs.
[0042] Example 3: In vitro verification of CHON-MSCs’ stronger ability to inhibit chondrocyte apoptosis
[0043] (A) Chondrocytes were obtained from Shanghai Anwei Biotechnology Co., Ltd.;
[0044] (II) Main reagents: DMEM / F12 culture medium, Corning, USA; IL-1β, Proteintech, USA; 0.25% trypsin-0.02% EDTA, Gibco, USA; apoptosis kit, purchased from Hangzhou Lianke Biotechnology Co., Ltd.; cell culture equipment: 100 mm diameter cell culture dishes and cell culture plates; if no specific technology or conditions are specified in the examples, the technology or conditions described in the literature in this field or the product instructions shall be followed; if the manufacturer of the reagents or instruments is not specified, they can be purchased through regular channels;
[0045] (III) Solution preparation:
[0046] DMEM / F-12 complete medium: add 450 mL of DMEM / F12 medium to 50 mL of FBS, then add 100 IU / mL of penicillin and 100 μg / mL of streptomycin;
[0047] (IV) Chondrocyte apoptosis staining protocol: Chondrocytes were resuspended in 100 μL PBS and transferred to a flow cytometry tube. 1×10 6 Add 5 μL FITC anti-human-Annexin V antibody and 10 μL PE anti-human-PI antibody to each cell, incubate at room temperature in the dark for 5 min, and then put it on the machine;
[0048] 5. Flow cytometry staining results Figure 7 As shown in the results, compared with traditional MSCs, CHON-MSCs down-regulated chondrocyte apoptosis to a greater extent than traditional MSCs, that is, CHON-MSCs can inhibit chondrocyte apoptosis better than traditional MSCs.
[0049] Example 4: In vitro verification of CHON-MSCs’ stronger chondrogenic differentiation ability
[0050] (I) Main reagents: Chondrogenic differentiation kit, STEMCELL Technologies, Canada; 0.25% trypsin-0.02% EDTA, Gibco, USA; cell culture equipment, 15 mL centrifuge tube;
[0051] (II) Solution preparation:
[0052] Complete chondrogenic differentiation medium: 1 mL 20× chondrogenic supplement, 19 mL basal medium and 200 μL 200 mM L-Glutamine into a 50 mL centrifuge tube, and add 1‰ volume of penicillin-streptomycin solution and mix well;
[0053] (III) Cartilage tissue detection plan: On the 21st day of culture, cartilage tissue masses from each group were collected, the diameter of the cartilage tissue masses was detected, the wet weight was measured by analytical balance, and the dry weight was measured after freeze-drying;
[0054] (IV) Results of chondrogenic differentiation Figure 8 As shown, Figure 8 Middle a is the morphological comparison of cartilage-like tissue masses. Figure 8 bd in the middle are comparisons of cartilage-like tissue mass diameter, dry weight and wet weight respectively. The results showed that compared with traditional MSCs, the diameter, dry weight and wet weight of CHON-MSCs were higher than those of traditional MSCs, that is, CHON-MSCs have better chondrogenic differentiation ability than traditional MSCs.
[0055] Example 5: OA animal model experiment
[0056] (I) Animal modeling: Destabilization of medial meniscus (DMM) of the knee joint: find the medial meniscus ligament and medial collateral ligament of the rat, and cut the medial collateral ligament; use micro forceps and micro scissors to cut the medial meniscus ligament, then the medial meniscus will be exposed, cut the medial meniscus, cut the anterior cruciate ligament, then clean the wound, reposition the patellar ligament and muscle tissue, and suture the muscle and skin;
[0057] (II) Animal grouping and drug administration: The model animals were randomly divided into a model group, a traditional MSC group, and a CHON-MSC group. Drugs were administered by intra-articular injection after the animal model was established. The MSC treatment group was administered twice (2 weeks and 4 weeks after surgery); the dosage for rats was 1.0×10 6 cells / mouse, 50 μL was administered to each mouse. The final administration concentration was: 2.0×10 7 cells / mL. Six weeks after the start of drug administration, the rats in each group were killed and various indicators were tested;
[0058] (III) OA animal model index detection: The rats in each group were killed, and the knee joint tissue samples were obtained. The muscle tissue around the knee joint of the rats was carefully separated with a scalpel. After being fixed with 4% paraformaldehyde for 48 hours, the rats in each group were subjected to X-ray imaging examination.
[0059] (IV) X-ray results Fig. 9 As shown: X-rays of the model group showed a large number of osteophytes, obvious subchondral bone sclerosis and severe joint space narrowing. Compared with traditional MSCs, the CHON-MSC group could effectively reduce the joint space narrowing, showing a better therapeutic effect on rat osteoarthritis.
[0060] Compared with traditional MSCs, CHON-MSCs of the present invention have high osteogenic and chondrogenic potentials, and thus can also play a better role in the treatment of other bone and joint diseases and osteoporosis.
[0061] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential, characterized in that: The cell surface of the MSC subpopulation with high osteogenic and chondrogenic potential simultaneously highly expresses PDGFRA, IL1R1 and IL18R1.
2. A method for sorting a subpopulation of mesenchymal stem cells with high osteogenic and chondrogenic potential according to claim 1, characterized in that: The following steps are involved: Clinical treatment-grade MSCs were surface stained with different fluorescently labeled flow cytometric antibody combinations, and the stained cells were resuspended in PBS and sorted using a flow cytometer; the antibody combination included antibodies that recognized antigens PDGFRA, IL1R1, and IL18R1.
3. Use of the mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential according to claim 1 in the preparation of a drug for treating knee osteoarthritis.
4. Use of the mesenchymal stem cell subpopulation with high osteogenic and chondrogenic potential according to claim 1 in the preparation of a drug for treating osteoporosis.
